We previously demonstrated that TP-0903, a small molecule originally developed as an AXL inhibitor [18], is a multikinase inhibitor with low nM activity against AURKA/B, Chk1/2, and other cell cycle regulators and has activity in models of drug-resistant acute myeloid leukemia with wildtype TP53 [19]. This evidence concerns the gene AURKA and acute myeloid leukemia.